MARKET

YMAB

YMAB

Y-mAbs Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

26.10
+2.97
+12.84%
Closed 19:52 03/31 EDT
OPEN
24.37
PREV CLOSE
23.13
HIGH
26.30
LOW
22.71
VOLUME
371.68K
TURNOVER
--
52 WEEK HIGH
36.29
52 WEEK LOW
14.16
MARKET CAP
1.04B
P/E (TTM)
-11.3542
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 8 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average YMAB stock price target is 39.14 with a high estimate of 41.00 and a low estimate of 35.00.

EPS

YMAB News

More
  • Y-mAbs Therapeutics, Inc. (YMAB) CEO Claus Moller on Q4 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript · 03/13 03:05
  • Y-mAbs Therapeutics EPS beats by $0.05
  • seekingalpha · 03/13 01:03
  • Y-mAbs Announces 2019 Financial Results and Recent Corporate Developments
  • GlobeNewswire · 03/12 21:01
  • Y-mAbs Therapeutics, Inc. to Host Earnings Call
  • ACCESSWIRE · 03/12 19:30

Industry

Biotechnology & Medical Research
-0.49%
Pharmaceuticals & Medical Research
-0.25%

Hot Stocks

Symbol
Price
%Change

About YMAB

Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing the therapeutic products for the treatment of cancer. Its product pipeline includes naxitamab and omburtamab. The Company’s lead antibody programs target GD2 and B7-H3. The Company develops naxitamab for the treatment of pediatric patients with relapsed or refractory (R/R), neuroblastoma (NB), and radiolabeled omburtamab for the treatment of pediatric patients with central nervous system (CNS), leptomeningeal metastases (LM). The Company also creates humanized, affinity matured bispecific antibodies. In addition, the Company has two B7-H3 targeting product candidates, omburtamab- diethylenetriamine pentaacetate (DTPA) and huB7-H3, which are in pre-clinical stage.
More

Webull offers kinds of Y-mAbs Therapeutics, Inc stock information, including NASDAQ:YMAB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, YMAB stock news, and many more online research tools to help you make informed decisions.